Home » Newsletters » BioWorld Science

BioWorld Science

June 22, 2006

View Archived Issues

BTG closes busy year

AZD-2171, combined with chemotherapy or EGFR inhibitor, is active in patients with solid tumors

Focus on BAY-579352 at ASCO

ISTA licenses new investigational glaucoma products from Senju

NeoRx changes name to Poniard Pharmaceuticals

Epeius awarded grant to support cancer gene therapy trials with Rexin-G

MQX-503 studied in European trial for Raynaud's phenomenon

Exenatide snapshots from the American Diabetes Association annual meeting

Synergistic weight loss seen with bupropion/naltrexone combination

Galiximab/rituximab combination feasible and active in non-Hodgkin's lymphoma

GDNF gene therapy is neuroprotective in Huntington's disease / News in Context

Discovery and potential preclinical antiobesity efficacy of PSN-632408, a GPR119 agonist

NicOx granted generic name naproxcinod for HCT-3012

Phase Ia study of Reolysin with radiation completes enrollment

ARQ-501 enters phase II development

New phase II study investigates PXD-101 for mesothelioma

Aeolus selects AEOL-11207 as first development candidate

New preclinical findings for CF-101

U.K. acute pain study of cannabinor cleared to begin

Praecis ceases efforts to license or sell Plenaxis

Three-hour imaging time point most appropriate for ThromboView

Immunological bioactivity and antiviral properties of VGV-1 confirmed

Lenalidomide study snapshots from the European Hematology Association congress

Study evaluates AVE-7688 pharmacodynamics

Cardioprotective activity of first generation inhibitor of malonyl-CoA decarboxylase

Orphan drug designation for Anthim

Remicade sBLA in psoriatic arthritis accepted for filing

Recent patents describe new therapeutic strategies for endocrine-related disorders

Novel antibacterial agents disclosed in two recent Pfizer patents

New fixed-dose formulations for BPH described in recent GSK patent

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026